Volume 7, Issue 6, November 2019, Page: 169-174
A Radiomics Model in Predicting Recurrence Time of Small Hepatocellular Carcinoma After Hepatectomy Base on MR by ANN
Weiwei Wang, Radiological Department, The Fifth Medical Center of PLA General Hospital, Beijing, China
Weimin An, Radiological Department, The Fifth Medical Center of PLA General Hospital, Beijing, China
Jinghui Dong, Radiological Department, The Fifth Medical Center of PLA General Hospital, Beijing, China
Jianzeng Zhang, Radiological Department, The Fifth Medical Center of PLA General Hospital, Beijing, China
Peng Li, Radiological Department, The Fifth Medical Center of PLA General Hospital, Beijing, China
Zhenjie Wu, China School of Microelectronics, Xidian University, Xi'an, China
Fangfang Shi, Radiological Department, The Fifth Medical Center of PLA General Hospital, Beijing, China
Mengmeng Zhang, Radiological Department, The Fifth Medical Center of PLA General Hospital, Beijing, China
Received: Oct. 28, 2019;       Accepted: Nov. 22, 2019;       Published: Dec. 11, 2019
DOI: 10.11648/j.ajim.20190706.16      View  76      Downloads  43
Abstract
Objective: The recurrence time of small hepatocellular carcinoma (sHCC) after resection are heterogeneous. Prediction the recurrence time of sHCC after resection is propitious to the fine management and individualized treatment of patients with sHCC, especially preoperative noninvasive. Methods: Collected the patients who with SHCC resection, and performed MR before operation one month long, cases with complete follow-up data in the Fifth Medical Center of the Chinese PLA General Hospital during January 2010 to January 2017. Abstract radiographic features of MR LAVA sequence Mask images by pyradiomics and input ANN. Results: A total of 179 cases were enroll into the study, of which 89 were early recurrence (≤24 months) cases and 90 were non-early recurrence (>24 months) cases. Abstract 121 radiographic features of MR LAVA sequence Mask images. Input ANN model into training group (150 cases) and test group (29 cases), the AUC value is 0. 64. The correlation factors of AFP and tumor size were 0.03 and 0.06 respectively. Conclusion: the ANN model of Mask features of MR T1 LAVA sequence can be used to predict the recurrence time of sHCC after resection before the operation, to establish the operative strategy and determine the Image examination frequency of postoperative follow-up.
Keywords
ANN, MR, eHCC, Recurrence Time
To cite this article
Weiwei Wang, Weimin An, Jinghui Dong, Jianzeng Zhang, Peng Li, Zhenjie Wu, Fangfang Shi, Mengmeng Zhang, A Radiomics Model in Predicting Recurrence Time of Small Hepatocellular Carcinoma After Hepatectomy Base on MR by ANN, American Journal of Internal Medicine. Vol. 7, No. 6, 2019, pp. 169-174. doi: 10.11648/j.ajim.20190706.16
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Dong S, Wang Z, Wu L, et al. Effect of surgical margin in R0 hepatectomy on recurrence-free survival of patients with solitary hepatocellular carcinomas without macroscopic vascular invasion. Medicine (Baltimore). 2016 Nov; 95 (44): e5251.
[2]
Lin CW, Chen YS, Lin CC, et al. Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. Clin Transl Gastroenterol. 2018 Jul 2; 9 (6): 166.
[3]
Akateh C, Pawlik TM, Cloyd JM. Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B? Ann Transl Med. 2018 Oct; 6 (20): 397.
[4]
Yaprak O, Acar S, Ertugrul G, et al. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol. 2018 Oct 15; 10 (10): 336-343.
[5]
Casadei Gardini A, Marisi G, Canale M, et al. Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. Onco Targets Ther. 2018 Oct 5; 11: 6555-6567.
[6]
Ali MA, Li WF, Wang JH, et al. Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan. HPB (Oxford). 2016 Oct; 18 (10): 851-860.
[7]
Lee KF, Chong CCN, Fong AKW, et al. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center. Hepatobiliary Surg Nutr. 2018 Oct; 7 (5): 320-330.
[8]
Zhang Y, Chen SW, Liu LL, et al. A model combining TNM stage and tumor size shows utility in predicting recurrence among patients with hepatocellular carcinoma after resection. Cancer Manag Res. 2018 Sep 20; 10: 3707-3715.
[9]
Tokumitsu Y, Sakamoto K, Tokuhisa Y, et al. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett. 2018 Apr; 15 (4): 4411-4422.
[10]
Zhang W, Lai SL, Chen J, et al. Validated preoperative computed tomography risk estimation for postoperative hepatocellular carcinoma recurrence. World J Gastroenterol. 2017 Sep 21; 23 (35): 6467-6473.
[11]
Setsu T, Tsuchiya A, Watanabe T, et al. Early Detection of Hepatocellular Carcinoma Recurrence Using the Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein. Case Rep Gastroenterol. 2017 Mar 21; 11 (1): 142-147.
[12]
Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY). 2017 Jun; 42 (6): 1695-1704.
[13]
Xiao DD, Yan PF, Wang YX, et al. Glioblastoma and primary central nervous system lymphoma: Preoperative differentiation by using MRI-based 3D texture analysis. Clin Neurol Neurosurg. 2018 Oct; 173: 84-90.
[14]
Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014 Jun 3; 5: 4006.
[15]
Zou H, Zhu CZ, Wang C, et al. Recurrence of Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy. Am J Med Sci. 2017 Sep; 354 (3): 262-267.
[16]
Zheng J, Chou JF, Gönen M, et al. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Ann Surg. 2017 Oct; 266 (4): 693-701.
[17]
Park YK, Song SK, Kim BW, et al. Conditional Survival Analysis Demonstrates that Recurrence Risk of Surgically Treated Hepatocellular Carcinoma Evolves with Time. J Gastrointest Surg. 2017 Aug; 21 (8): 1237-1244.
[18]
Ikeda K, Kawamura Y, Kobayashi M, et al. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci. 2017 Oct; 62 (10): 2932-2942.
[19]
Jiang J, Hu H, Liu R, et al. Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma. Medicine (Baltimore). 2017 Aug; 96 (32): e7390.
[20]
Field WBS, Rostas JW, Philps P, et al. Wide versus narrow margins after partial hepatectomy for hepatocellular carcinoma: Balancing recurrence risk and liver function. Am J Surg. 2017 Aug; 214 (2): 273-277.
[21]
Bodzin AS, Lunsford KE, Markovic D, et al. Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics. Ann Surg. 2017 Jul; 266 (1): 118-125.
[22]
Ryu T, Takami Y, Wada Y, et al. Double-and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A. J Gastrointest Surg. 2017 Jun; 21 (6): 957-966.
[23]
Zhang X, Li C, Wen T. Distinct Recurrence Risk Factors for Intrahepatic Metastasis and Multicenter Occurrence After Surgery in Patients with Hepatocellular Carcinoma: What Is More Is About Different Therapeutic Strategies. J Gastrointest Surg. 2017 Dec; 21 (12): 2148-2149.
[24]
Gan W, Huang JL, Zhang MX, et al. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. J Surg Oncol. 2018 Jun; 117 (7): 1540-1547.
[25]
Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 1; 3 (4): 493-500.
[26]
Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story. Ann Surg. 2017 Mar; 265 (3): 557-564.
[27]
Shin SK, Kim YS, Shim YS, et al. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore). 2017 Aug; 96 (33): e7761.
[28]
Aerts HJ. The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review. JAMA Oncol. 2016 Dec 1; 2 (12): 1636-1642.
[29]
Smith KE, Kelly AC, Min CG, et al. Acute Ischemia Induced by High-Density Culture Increases Cytokine Expression and Diminishes the Function and Viability of Highly Purified Human Islets of Langerhans. Transplantation. 2017 Nov; 101 (11): 2705-2712.
Browse journals by subject